Viral kinetics in patients with chronic hepatitis C treated with the serine protease inhibitor BILN 2061.

Abstract

We analysed viral kinetics from a 2-day treatment with BILN 2061, a serine protease inhibitor of hepatitis C virus, in patients chronically infected with genotype 1 hepatitis C virus. The efficiency (E), describing inhibition of viral production, was above 99.45% in all patients with minor or moderate fibrosis receiving doses of 200mg and 500 mg twice daily and larger than in previous studies for interferon-based treatments. However, epsilon was slightly smaller in patients with cirrhosis given 200mg and markedly smaller in patients given 25 mg. Estimates of viral clearance and infected-cell loss support conclusions on these rates and on treatment mechanisms from previous studies on interferon-alpha-based treatments.

• Authors: Eva Herrmann, Stefan Zeuzem, Christoph Sarrazin, Holger Hinrichsen, Yves Benhamou, Michael P Manns, Markus Reiser, Henk Reesink, José L Calleja, Xavier Forns, Gerhard G Steinmann, Gerhard Nehmiz
• Journal: Antiviral therapy (Antivir Ther) Vol. 11 Issue 3 Pg. 371-6 ( 2006) ISSN: 1359-6535 [Print] England
• PMID: 16759054 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiviral Agents
• BILN 2061
• Carbamates
• Interferon-alpha
• Macrocyclic Compounds
• Quinolines
• RNA, Viral
• Serine Proteinase Inhibitors
• Thiazoles

Topics

• Adult
• Antiviral Agents (therapeutic use)
• Area Under Curve
• Carbamates (administration & dosage, pharmacokinetics, therapeutic use)
• Female
• Hepacivirus (drug effects)
• Hepatitis C, Chronic (drug therapy, virology)
• Humans
• Interferon-alpha (therapeutic use)
• Kinetics
• Macrocyclic Compounds (administration & dosage, pharmacokinetics, therapeutic use)
• Male
• Middle Aged
• Models, Biological
• Quinolines (administration & dosage, pharmacokinetics, therapeutic use)
• RNA, Viral (blood)
• Serine Proteinase Inhibitors (administration & dosage, pharmacokinetics, therapeutic use)
• Thiazoles (administration & dosage, pharmacokinetics, therapeutic use)